{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:55:25Z","timestamp":1781585725872,"version":"3.54.5"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Off\u2010label use of anticholinergic agents (atropine eye drops) administered sublingually are a first\u2010line treatment in standard clinical practice in France to treat sialorrhea in patients with neurological conditions. The ability and willingness to using and administering such medication have become key factors to ensure safe and effective therapy. Given that the critical aspects for ophthalmic product development differ from those for oral medicine, the objectives of this study were to investigate patient acceptability of atropine eye drops for treating sialorrhea. A multi\u2010centric, cross\u2010sectional study using the CAST\u2014ClinSearch Acceptability Score Test methodology was conducted in France between February 2021 and April 2023. In total, 31 evaluations were collected. Most patients were males (74.2%) and the mean age was 51.6\u2009\u00b1\u200920\u2009years. Poor acceptability was reported in real\u2010life settings. A lack of a suitable administration device combined with excessive saliva flow and patient disabilities made it difficult to ensure the required dose intake. Due to the bitter taste of the drug, poor palatability of the product appeared to be a key concern for oral administration. Designing a suitable form of atropine in accordance with the specificities of patients with neurological disabilities is needed to ensure the effective treatment of sialorrhea.<\/jats:p>","DOI":"10.1002\/prp2.70250","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:34:35Z","timestamp":1779442475000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acceptability of Atropine Eyedrops Administered Sublingually for Sialorrhea Treatment Related to Neurological Conditions"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3760-7178","authenticated-orcid":false,"given":"Hugues","family":"Michelon","sequence":"first","affiliation":[{"name":"Service de Pharmacie, H\u00f4pital Sainte\u2010P\u00e9rine, Assistance Publique\u2010H\u00f4pitaux de Paris (AP\u2010HP), Universit\u00e9 Paris\u2010Saclay  Paris France"},{"name":"Service de Pharmacie, H\u00f4pital Raymond Poincar\u00e9, AP\u2010HP Universit\u00e9 Paris\u2010Saclay  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Lef\u00e8vre\u2010Dognin","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Soins Prolong\u00e9s Complexes, H\u00f4pital Sainte\u2010P\u00e9rine, AP\u2010HP Universit\u00e9 Paris\u2010Saclay  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Paquereau","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Soins de R\u00e9\u00e9ducation Post\u2010R\u00e9animation, H\u00f4pital Raymond Poincar\u00e9, AP\u2010HP Universit\u00e9 Paris\u2010Saclay  Garches France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eblle","family":"Guidoni","sequence":"additional","affiliation":[{"name":"Service de Pharmacie, H\u00f4pital Sainte\u2010P\u00e9rine, Assistance Publique\u2010H\u00f4pitaux de Paris (AP\u2010HP), Universit\u00e9 Paris\u2010Saclay  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Boudy","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de R&amp;D Gal\u00e9nique Agence G\u00e9n\u00e9rale Des Equipements et Produits de Sant\u00e9 (AGEPS), AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Ruiz","sequence":"additional","affiliation":[{"name":"ClinSearch, 110 Avenue Pierre Brossolette  Malakoff France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Vallet","sequence":"additional","affiliation":[{"name":"ClinSearch, 110 Avenue Pierre Brossolette  Malakoff France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/DNND.S168353"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419888601"},{"issue":"2","key":"e_1_2_12_4_1","first-page":"17","article-title":"Interventions for Drooling in Children With Cerebral Palsy","author":"Walshe M.","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22305"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05627-4"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ipd.12219"},{"issue":"5","key":"e_1_2_12_8_1","first-page":"2","article-title":"Treatment for Sialorrhea (Excessive Saliva) in People With Motor Neuron Disease\/Amyotrophic Lateral Sclerosis","author":"Young C. A.","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.02.007"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282x20170033"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1708552"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-019-02000-4"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2015.05.010"},{"key":"e_1_2_12_14_1","first-page":"2628","article-title":"Sialorrhea: A Management Challenge","volume":"69","author":"Hockstein N. G.","year":"2004","journal-title":"American Family Physician"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rehab.2020.101467"},{"key":"e_1_2_12_16_1","volume-title":"Neurotoxine de Clostridium Botulinum de Type A (XEOMIN)","author":"Haute Autorit\u00e9 de Sant\u00e9 (HAS)","year":"2022"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.10.039"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14757"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.5430\/crim.v3n3p82"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.12.028"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2012.04.022"},{"key":"e_1_2_12_22_1","volume-title":"Guideline on Pharmaceutical Development of Medicines for Paediatric Use","author":"European Medicine Agency","year":"2013"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2014.03.057"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2424-3"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11080368"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-019-1337-2"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12080746"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijpp\/riab077"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12547"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12829"},{"key":"e_1_2_12_31_1","volume-title":"Letter of Support for an Acceptability Score Test in Relative Acceptability Testing for Oral Medicines in Children Under 12\u2009Years of Age","author":"European Medicines Agency","year":"2023"},{"key":"e_1_2_12_32_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use considerations (ICH) \u201cGuideline Q8 (R2) on Pharmaceutical Development \u201d(2009)."},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2003.12.009"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.77.6.364"},{"key":"e_1_2_12_35_1","volume-title":"Reflection Paper on the Pharmaceutical Development of Medicines for Use in the Older Population","author":"European Medicine Agency","year":"2020"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101721"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70250","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.70250","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:18:38Z","timestamp":1781583518000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.70250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/prp2.70250"],"URL":"https:\/\/doi.org\/10.1002\/prp2.70250","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2025-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70250"}}